Canandaigua National Bank & Trust Co. Buys New Position in Eli Lilly and Company $LLY

Key Points

• Canandaigua National Bank & Trust Co. purchased 7,511 Eli Lilly shares worth approximately $9.0 million during the second quarter, making LLY 0.8% of its portfolio. Institutional investors collectively own 82.53% of the company.
• Lilly’s pipeline received positive attention after the FDA granted Breakthrough Therapy designation to olomorasib for advanced pancreatic cancer, while limited early access to obesity drug retatrutide underscores demand for its next-generation treatments.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $1,283.64, but Lilly faces elevated valuation risk, strong competition from Novo Nordisk, and scrutiny around upcoming earnings, pricing, and obesity-drug demand.

Canandaigua National Bank & Trust Co. bought a new stake in Eli Lilly and Company (NYSE:LLY - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 7,511 shares of the company's stock, valued at approximately $9,009,000. Eli Lilly and Company makes up 0.8% of Canandaigua National Bank & Trust Co.'s portfolio, making the stock its 28th largest holding.

Other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in Eli Lilly and Company by 1.2% in the 4th quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company's stock valued at $88,087,193,000 after buying an additional 1,006,885 shares during the last quarter. State Street Corp lifted its position in Eli Lilly and Company by 1.8% during the 4th quarter. State Street Corp now owns 35,361,916 shares of the company's stock worth $38,002,744,000 after buying an additional 635,358 shares in the last quarter. Morgan Stanley boosted its stake in shares of Eli Lilly and Company by 2.7% during the 4th quarter. Morgan Stanley now owns 15,593,019 shares of the company's stock worth $16,757,510,000 after buying an additional 407,166 shares during the last quarter. Capital World Investors boosted its stake in shares of Eli Lilly and Company by 0.4% during the 4th quarter. Capital World Investors now owns 15,031,750 shares of the company's stock worth $16,154,619,000 after buying an additional 61,851 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Eli Lilly and Company by 10.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,910,505 shares of the company's stock valued at $16,024,022,000 after acquiring an additional 1,432,069 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The FDA granted Breakthrough Therapy designation to Lilly’s investigational KRAS G12C inhibitor olomorasib for previously treated patients with advanced pancreatic cancer. The designation may accelerate development and regulatory interaction for a potential new oncology revenue stream. Lilly's olomorasib receives FDA Breakthrough Therapy designation
• Positive Sentiment: Lilly is collaborating with Amplia Therapeutics to test olomorasib with narmafotinib in a Phase 1b/2b trial for advanced non-small cell lung cancer. The combination could expand olomorasib’s potential use beyond pancreatic and other cancers, although it remains an early-stage opportunity. Amplia collaboration with Lilly on olomorasib trial
• Positive Sentiment: Lilly will allow a limited number of patients to seek special access to experimental obesity drug retatrutide before potential FDA approval. The move highlights demand for the next-generation therapy and keeps attention on Lilly’s obesity pipeline. Lilly to offer early access to retatrutide
• Neutral Sentiment: Lilly’s upcoming earnings report is the immediate focus. Investors will look for continued prescription and revenue momentum from Mounjaro and Zepbound, management’s outlook, and updates on manufacturing capacity and pricing. Will Mounjaro and Zepbound drive Lilly's Q2 results?
• Negative Sentiment: Investor expectations are elevated after Lilly’s powerful multiyear rally and roughly $1 trillion-plus valuation. Valuation analyses question whether projected cash flows justify the current price, increasing downside risk if earnings or guidance fall short. Eli Lilly stock looks below fair value on cash flow
• Negative Sentiment: Competition in the obesity-drug market remains a concern, as Novo Nordisk is attempting to regain ground. Any evidence of slowing demand, pricing pressure or improved rival products could challenge Lilly’s premium growth expectations. Obesity battle heats up between Novo and Lilly

Analysts Set New Price Targets

LLY has been the topic of a number of recent research reports. Berenberg Bank lifted their target price on Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the company a "hold" rating in a research report on Monday, June 22nd. Wolfe Research reiterated an "outperform" rating and set a $1,350.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, May 21st. The Goldman Sachs Group reissued a "buy" rating and issued a $1,283.00 price objective on shares of Eli Lilly and Company in a report on Friday, May 22nd. Barclays raised their target price on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an "overweight" rating in a research note on Monday, May 4th. Finally, Rothschild & Co Redburn upped their price target on shares of Eli Lilly and Company from $880.00 to $900.00 in a research report on Thursday, May 7th. Two analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $1,283.64.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $1,115.68 on Wednesday. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The business's 50 day moving average price is $1,154.75 and its two-hundred day moving average price is $1,044.52. The company has a market cap of $1.05 trillion, a PE ratio of 39.63, a price-to-earnings-growth ratio of 1.39 and a beta of 0.51. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,249.45.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company's payout ratio is presently 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source